S. Treon

S. Treon, S. Broitman, P. Thomas, 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

CXCR4 in Waldenström’s Macroglobulinema: chances and challenges

C. Buske, S. Treon, Z. Hunter, 2020, Leukemia.

Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study

S. Treon, M. Ramgopal, S. Coutre, 2022, Open forum infectious diseases.

Waldenström’s disease

S. Treon, G. Merlini, 2004 .

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

T. Lister, B. Barlogie, M. Dhodapkar, 2003, Seminars in oncology.

Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.

S. Treon, Z. Hunter, R. Ojha, 2011, Clinical lymphoma, myeloma & leukemia.

Report from the Sixth International Workshop on Waldenström's Macroglobulinemia.

S. Treon, G. Merlini, E. Morra, 2011, Clinical lymphoma, myeloma & leukemia.

IgA and IgG hypogammaglobulinemia in Waldenström’s macroglobulinemia

S. Treon, Z. Hunter, M. Morra, 2010, Haematologica.

Advances in the biology and treatment of Waldenström's macroglobulinemia: a report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden.

E. Kimby, S. Treon, M. Stone, 2009, Clinical lymphoma & myeloma.

XIII. Waldenström's macroglobulinaemia: an indolent B‐cell lymphoma with distinct molecular and clinical features

S. Treon, 2013, Hematological oncology.

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.

R. Advani, S. Treon, Z. Hunter, 2017, Blood.

Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome

S. Treon, Z. Hunter, J. Castillo, 2017, British journal of haematology.

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.

N. Mitsiades, C. Mitsiades, S. Treon, 2002, Blood.

ligand-induced apoptosis in human multiple myeloma cells Intracellular regulation of tumor necrosis factor-related apoptosis-inducing

N. Mitsiades, C. Mitsiades, S. Treon, 2002 .

Cells : Clinical Implications Antibody , Induces Cytotoxicity in Human Multiple Myeloma Mechanisms by which SGN-40 , a Humanized Anti-CD 40

N. Munshi, P. Richardson, C. Mitsiades, 2004 .

Recombinant humanized anti‐CD40 monoclonal antibody triggers autologous antibody‐dependent cell‐mediated cytotoxicity against multiple myeloma cells

P. Richardson, D. Chauhan, S. Treon, 2003, British journal of haematology.

Promotes Differentiation and Inhibits Apoptosis of JKB Acute Lymphoblastic Leukemia Cells

J. Decaprio, M. Urashima, A. Ogata, 1997 .

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

Michael A. Sellitto, D. Carrasco, Jian-jun Zhao, 2012, Blood.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.

P. Richardson, S. Treon, I. Ghobrial, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Resveratrol Exerts AntiproliferativeActivity and Induces Apoptosis inWaldenstro« m’s Macroglobulinemia

F. Dammacco, S. Treon, A. Roccaro, 2008 .

Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia.

S. Treon, Z. Hunter, A. Branagan, 2006, Archives of ophthalmology.

miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.

W. Kuo, G. Pinkus, M. Bouxsein, 2014, Cancer research.

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application

P. Richardson, Shaji K. Kumar, D. Chauhan, 2005, British journal of haematology.

Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.

Sherine F. Elsawa, S. Treon, S. R. Walker, 2020, Epigenomics.

Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia

L. Trippa, D. Steensma, S. Treon, 2021, Blood advances.

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.

N. Munshi, M. Samur, S. Treon, 2018, Blood advances.

Increased Sensitivity to DNA Damage Multiple Myeloma Cells Is Associated with Ku86 Variant Expression and Function in

Y. Shima, G. Teoh, D. Chauhan, 2013 .

Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone

M. Urashima, A. Ogata, L. Pilarski, 1999 .

in patients with multiple myeloma Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels

Y. Shima, L. Pilarski, A. Belch, 2000 .

The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.

S. Treon, K. Anderson, K. Anderson, 2000, Seminars in oncology.

Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism

M. Urashima, A. Ogata, P. Pandey, 1997, Oncogene.

Receptor activator of nuclear factor-kappa B (RANK) ligand expression: In human multiple myeloma cells.

N. Munshi, P. Richardson, N. Mitsiades, 2001 .

CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib

M. Kersten, T. Ganz, S. Treon, 2017, Haematologica.

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

S. Treon, I. Ghobrial, J. Castillo, 2020, Blood.

Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.

E. Kimby, M. Dimopoulos, D. Maloney, 2006, Clinical lymphoma & myeloma.

Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

J. Byrd, E. Kimby, S. Treon, 2003, Seminars in oncology.

Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma.

Hao Wu, N. Gray, S. Ficarro, 2020, ACS medicinal chemistry letters.

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

N. Gray, Qingsong Liu, D. McMillin, 2014, ACS chemical biology.

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

E. Kimby, N. Munshi, R. Kyle, 2013, British journal of haematology.

Systemic Light Chain Amyloidosis - Panel Members

A. Krishnan, S. Singhal, C. Huff, 2014 .

Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia

S. Treon, N. Raje, Z. Hunter, 2021, Leukemia.

Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials

S. Treon, Z. Hunter, J. Castillo, 2020, HemaSphere.

What is new in the treatment of Waldenstrom macroglobulinemia?

S. Treon, J. Castillo, 2019, Leukemia.

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

D. Esseltine, S. Treon, I. Ghobrial, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel biologically based therapies for Waldenstrom's macroglobulinemia.

P. Richardson, N. Mitsiades, C. Mitsiades, 2003, Seminars in oncology.

A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas

N. Munshi, N. Gray, Jinhua Wang, 2022, Blood advances.

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

S. Treon, A. Roccaro, A. Sacco, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders

M. Davids, S. Treon, J. Castillo, 2016, Cancer journal.

Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib

S. Treon, J. Castillo, S. Sarosiek, 2021, British journal of haematology.

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

S. Treon, Z. Hunter, L. Ioakimidis, 2009, Clinical lymphoma & myeloma.

Concepts in use of high-dose methotrexate therapy.

S. Treon, B. Chabner, 1996, Clinical chemistry.

Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H)

J. Kutok, G. Pinkus, M. Shipp, 2006, Clinical Cancer Research.

How I treat Waldenström macroglobulinemia.

S. Treon, 2009, Blood.

How I treat Waldenström macroglobulinemia.

S. Treon, 2009, Blood.

How I treat Waldenström macroglobulinemia.

S. Treon, 2009, Blood.

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

J. Byrd, U. Jaeger, T. Shanafelt, 2018, British journal of haematology.

Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.

J. Kutok, Jiangwen Zhang, N. Munshi, 2007, Experimental hematology.

Multicenter ClinicalTrial of Bortezomib in Relapsed / Refractory Waldenstrom ’ s Macroglobulinemia : Results of WMCTGTrial 03-248

R. Advani, S. Treon, Z. Hunter, 2007 .

A SCID-hu in vivo model of human Waldenström macroglobulinemia.

J. Kutok, N. Munshi, P. Tassone, 2005, Blood.

Extended rituximab therapy in Waldenström's macroglobulinemia.

E. Kimby, F. Preffer, S. Treon, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.

L. Staudt, W. Chan, W. Wilson, 2022, Blood.

Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound

S. Treon, Z. Hunter, J. Castillo, 2018, American journal of hematology.

Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia

S. Verselis, E. Fox, S. Treon, 2009, British journal of haematology.

Whole Genome Sequencing Reveals a Widely Expressed Mutation (MYD88 L265P) with Oncogenic Activity in Waldenstrom's Macroglobulinemia

D. Skifter, S. Lincoln, J. Laramie, 2011 .

A Somatic Variant in MYD88 (L265P) Revealed by Whole Genome Sequencing Differentiates Lymphoplasmacytic Lymphoma From Marginal Zone Lymphomas

N. Harris, G. Pinkus, S. Rodig, 2011 .

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.

S. Treon, Z. Hunter, L. Ioakimidis, 2011, Blood.

Clonal architecture of CXCR4 WHIM‐like mutations in Waldenström Macroglobulinaemia

R. Advani, J. Zehnder, S. Treon, 2016, British journal of haematology.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia

M. Dimopoulos, C. Buske, S. Treon, 2018, The New England journal of medicine.

Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.

S. Treon, Z. Hunter, L. Ioakimidis, 2012, Clinical lymphoma, myeloma & leukemia.

type and Waldenström macroglobulinemia for monoclonal gammopathy of undetermined significance of the IgM Hyperphosphorylated paratarg-7: a new molecularly defined risk factor

M. Dimopoulos, M. Pfreundschuh, S. Treon, 2013 .

Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia.

M. Ziepert, M. Dimopoulos, M. Pfreundschuh, 2011, Blood.

The HMG‐CoA inhibitor, simvastatin, triggers in vitro anti‐tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia

S. Treon, A. Roccaro, A. Sacco, 2008, British journal of haematology.

TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia

S. Treon, Z. Hunter, J. Castillo, 2017, British journal of haematology.

RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells

H. Husson, P. Pandey, S. Kharbanda, 1999, Oncogene.

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

R. Advani, M. Kersten, M. Dimopoulos, 2020, HemaSphere.

Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia

S. Treon, A. Branagan, J. Castillo, 2022, Expert review of anticancer therapy.

Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM

R. Advani, E. Kimby, B. Barlogie, 2014 .

Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.

Y. Shima, L. Pilarski, A. Belch, 2000, Blood.

Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels in patients with multiple myeloma

Y. Shima, L. Pilarski, A. Belch, 2000 .

Molecular Characterization of Waldenstrom's Macroglobulinemia Reveals Frequent Occurrence of Two B-Cell Clones Having Distinct IgH VDJ Sequences

T. Reiman, L. Pilarski, M. Mant, 2007, Clinical Cancer Research.

Molecular Characterization ofWaldenstrom ’ s Macroglobulinemia Reveals Frequent Occurrence of Two B-Cell Clones Having Distinct IgHVDJSequences

T. Reiman, L. Pilarski, M. Mant, 2007 .

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.

N. Munshi, P. Richardson, D. Chauhan, 2005, Cancer research.

Marine Oils in the Modulation of Colonic Flora and pH: Considerations for Colon Cancer

E. S. Fox, S. Treon, S. Broitman, 1989 .

Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells

N. Munshi, Hsiuyi Tseng, S. Treon, 2011, Leukemia & lymphoma.

Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.

E. Kimby, N. Mitsiades, C. Mitsiades, 2003, Seminars in oncology.

International prognostic scoring system for Waldenstrom macroglobulinemia.

J. Crowley, B. Barlogie, M. Dimopoulos, 2009, Blood.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Future therapeutic options for patients with Waldenström macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2016, Best practice & research. Clinical haematology.

Cell‐free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia

T. P. White, S. Treon, Z. Hunter, 2021, American journal of hematology.

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

Dennis L. Buckley, J. Bradner, N. Gray, 2017, Cell chemical biology.

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.

E. Kimby, D. Maloney, M. Hansen, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.

E. Kimby, M. Dimopoulos, D. Maloney, 2006, Blood.

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.

S. Treon, A. Roccaro, A. Sacco, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges with serum protein electrophoresis in assessing progression and clinical response in patients with Waldenström macroglobulinemia.

N. Lindeman, S. Treon, C. Tripsas, 2013, Clinical lymphoma, myeloma & leukemia.

Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

A. Pestronk, N. Munshi, S. Treon, 2003, Seminars in oncology.

CD14 mediated endogenous TNF-alpha release in HL60 AML cells: a potential model for CD14 mediated endogenous cytokine release in the treatment of AML.

S. Treon, R. Ulevitch, S. Broitman, 1994, Leukemia research.

Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms.

Ash A. Alizadeh, Ryan D. Morin, B. Nadel, 2022, Blood.

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia

N. Munshi, E. Baloglu, S. Treon, 2018, Clinical Cancer Research.

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab‐containing regimen

S. Treon, Z. Hunter, L. Ioakimidis, 2011, British journal of haematology.

Maintenance Rituximab is associated with improved clinical outcome in rituximab naı̈ve patients with Waldenstrom Macroglobulinaemia who respond

S. Treon, Z. Hunter, L. Ioakimidis, 2011 .

macroglobulinemia International prognostic scoring system for Waldenstrom's

J. Crowley, M. Dimopoulos, M. Dhodapkar, 2009 .

S. Treon, A. Branagan, J. Castillo, 2022, Hemato.

Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia

S. Treon, J. Castillo, K. Meid, 2018, Haematologica.

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.

S. Treon, N. Raje, Z. Hunter, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toward personalized treatment in Waldenström macroglobulinemia.

S. Treon, J. Castillo, 2017, Hematology. American Society of Hematology. Education Program.

Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma

S. Treon, G. Merlini, 2013 .

Waldenstrom's macrogloblinemia/ lymphoplasmacytic lymphoma.

S. Treon, E. Hatjiharissi, G. Merlini, 2008, Cancer treatment and research.

Multiple myeloma

S. Singhal, C. Huff, G. Tricot, 2001, Bone Marrow Transplantation.

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies

N. Mitsiades, S. Treon, R. Schlossman, 2001, Journal of immunotherapy.

Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens.

Y. Shima, L. Pilarski, A. Belch, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival

S. Treon, Z. Hunter, J. Castillo, 2018, British journal of haematology.

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

N. Harris, D. Skifter, S. Lincoln, 2012, The New England journal of medicine.

Detection of Kaposi's Sarcoma Herpesvirus Gene Sequences Multiple Myeloma Are Phenotypically and Functionally Normal Despite the Bone Marrow and Peripheral Blood Dendritic Cells From Patients With

D. Kufe, G. Teoh, D. Chauhan, 2008 .

Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis

G. Pinkus, M. Skinner, Shou-Jiang Gao, 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Cleavage-Mediated Regulation of Myd88 Signaling by Inflammasome-Activated Caspase-1

U. Potočnik, S. Treon, Iva Hafner-Bratkovič, 2022, Frontiers in Immunology.

Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma

Ryan D. Morin, R. Gascoyne, J. Connors, 2017, Oncoimmunology.

Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells

R. Gascoyne, J. Connors, M. Marra, 2015, Clinical Cancer Research.

Pathway-Catenin / BCL 9 β Therapeutic Tool by Targeting the Oncogenic Wnt / miR-30-5 p Functions as a Tumor Suppressor and Novel

W. Kuo, G. Pinkus, M. Bouxsein, 2014 .

Therapeutics , Targets , and Chemical Biology miR-30-5 p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt / b-Catenin / BCL 9 Pathway

W. Kuo, G. Pinkus, M. Bouxsein, 2014 .

Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications.

N. Munshi, R. Batchu, R. Goyal, 2006, Blood.

Genomic Landscape of Waldenström Macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2018, Hematology/oncology clinics of North America.

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic and Signaling Abnormalities in Waldenstrom’s Macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2017 .

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.

S. Treon, Z. Hunter, Guang Yang, 2014, Blood.

small somatic deletions associated with B-cell lymphomagenesis characterized by highly recurring MYD 88 and WHIM-like CXCR 4 mutations , The genomic landscape of Waldenstöm ' s Macroglobulinemia

S. Treon, Z. Hunter, Guang Yang, 2013 .

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.

J. Kutok, N. Munshi, P. Richardson, 2010, Blood.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

C. Hofmeister, A. Krishnan, S. Singhal, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.

N. Munshi, N. Mitsiades, C. Mitsiades, 2003, Blood.

p16INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells.

J. Decaprio, M. Urashima, A. Ogata, 1997, Blood.

Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia

M. Capelletti, S. Treon, A. Roccaro, 2018, PloS one.

Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia.

P. Pilarski, T. Reiman, L. Pilarski, 2008, Blood.

in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom’s macroglobulinemia

T. Reiman, L. Pilarski, A. Belch, 2008 .

Waldenstrom macroglobulinemia gene may contribute to disease progression in multiple myeloma and ) HAS1 Inherited and acquired variations in the hyaluronan synthase 1 (

P. Pilarski, T. Reiman, L. Pilarski, 2008 .

may contribute to disease progression in multiple myeloma and Inherited and acquired variations in the hyaluronan synthase 1 ( HAS 1 )

Pilarski, Hodges, P. Pilarski, 2008 .

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.

N. Gray, D. Weinstock, S. Treon, 2019, Blood.

microRNA aberrations in Waldenström macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2013, Clinical lymphoma, myeloma & leukemia.

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.

D. Chauhan, S. Treon, T. Hideshima, 2008, Blood.

antitumor activity in Waldenström macroglobulinemia Protein kinase C inhibitor enzastaurin induces in vitro and in vivo

S. Treon, T. Hideshima, A. Leontovich, 2008 .

Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.

S. Treon, T. Hideshima, A. Leontovich, 2007, Blood.

therapeutic applications B blockade in multiple myeloma: κ - Biologic sequelae of nuclear factor

N. Munshi, N. Mitsiades, C. Mitsiades, 2013 .

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.

N. Munshi, P. Richardson, N. Mitsiades, 2002, Blood.

Long‐term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia

P. L. Bergsagel, D. DeAngelo, S. Treon, 2014, American journal of hematology.

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.

P. Richardson, S. Ansell, A. Dispenzieri, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.

P. Richardson, D. DeAngelo, E. Jacobsen, 2008 .

Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM)

P. Richardson, S. Treon, I. Ghobrial, 2008 .

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

T. Libermann, N. Munshi, Marie G. Joseph, 2002, Proceedings of the National Academy of Sciences of the United States of America.

How we manage Bing–Neel syndrome

S. Treon, J. Castillo, 2019, British journal of haematology.

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.

N. Munshi, P. Richardson, C. Mitsiades, 2004, Cancer research.

Proteomic analysis of waldenstrom macroglobulinemia.

R. Fonseca, S. Treon, A. Leontovich, 2007, Cancer research.

CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications

N. Mitsiades, C. Mitsiades, Y. Shima, 2002, Journal of immunotherapy.

Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

Masaharu Akiyama, P. Richardson, N. Mitsiades, 2002, Oncogene.

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias

P. Richardson, S. Treon, A. Roccaro, 2008, Biologics : targets & therapy.

Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over‐expression of the ETS factor SPIB in Waldenström macroglobulinaemia

S. Treon, Z. Hunter, R. Carrasco, 2014, British journal of haematology.

Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.

M. Dimopoulos, S. Treon, E. Kastritis, 2010, Clinical lymphoma, myeloma & leukemia.

Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling.

S. Treon, Z. Hunter, R. Romih, 2018, Blood.

Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.

S. Treon, Z. Hunter, J. Castillo, 2020, Blood advances.

Targeted Therapies and Emerging Novel Treatment Approaches for Waldenström Macroglobulinemia.

S. Treon, A. Branagan, J. Castillo, 2022, Clinical lymphoma, myeloma & leukemia.

How to Sequence Therapies in Waldenström Macroglobulinemia

S. Treon, J. Castillo, S. Sarosiek, 2021, Current Treatment Options in Oncology.

Reducing treatment toxicity in Waldenström macroglobulinemia

S. Treon, J. Castillo, S. Sarosiek, 2021, Expert opinion on drug safety.

Clinical application of genomics in Waldenström macroglobulinemia

S. Treon, A. Branagan, J. Castillo, 2021, Leukemia & lymphoma.

CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors

S. Treon, Z. Hunter, J. Castillo, 2020, American journal of hematology.

CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors

S. Treon, Z. Hunter, J. Castillo, 2019, Blood.

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

S. Treon, Z. Hunter, J. Castillo, 2019, British journal of haematology.

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2019, Blood advances.

CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review

S. Treon, Z. Hunter, J. Castillo, 2019, Expert review of hematology.

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

L. Trippa, M. Capelletti, S. Treon, 2018, Blood.

Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2018, Clinical Cancer Research.

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.

S. Treon, I. Ghobrial, Z. Hunter, 2014, Blood.

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.

S. Treon, Z. Hunter, Guang Yang, 2014, Blood.

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

P. Richardson, S. Treon, I. Ghobrial, 2010, American journal of hematology.

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

M. Dimopoulos, R. Fonseca, G. Pangalis, 2003, Seminars in oncology.

Updates to the NCCN Guidelines

A. Krishnan, S. Singhal, C. Huff, 2013 .

A new era for Waldenstrom macroglobulinemia: MYD88 L265P.

S. Treon, Z. Hunter, 2013, Blood.

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

N. Munshi, N. Lindeman, S. Treon, 2013, Blood.

MYD 88 L 265 P in Waldenström macroglobulinemia , immunoglobulin M monoclonal gammopathy , and other B-cell lymphoproliferative disorders using conventional and quantitative allele-speci fi c polymerase chain reaction

N. Munshi, N. Lindeman, S. Treon, 2013 .

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia

J. Byrd, E. Kimby, D. Agus, 2001, Journal of immunotherapy.

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

G Muller, K. Anderson, P. Richardson, 2000, Blood.

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome

M. Kersten, E. Kimby, M. Dimopoulos, 2017, Haematologica.

Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia.

N. Lindeman, S. Treon, C. Tripsas, 2013, Clinical lymphoma, myeloma & leukemia.

Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia

M. Kersten, S. Treon, M. Spaargaren, 2016, Haematologica.

polymerase chain reaction disorders using conventional and quantitative allele-specific monoclonal gammopathy, and other B-cell lymphoproliferative MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M

N. Munshi, N. Lindeman, S. Treon, 2013 .

polymerase chain reaction disorders using conventional and quantitative allele-specific monoclonal gammopathy , and other B-cell lymphoproliferative MYD 88 L 265 P in Waldenström macroglobulinemia , immunoglobulin

N. Munshi, N. Lindeman, S. Treon, 2013 .

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.

C. Buske, S. Ansell, S. Treon, 2019, Blood.

Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes

M. Kersten, S. Treon, H. Rennke, 2016, British journal of haematology.

Histological transformation to diffuse large B‐cell lymphoma in patients with Waldenström macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2016, American journal of hematology.

Central nervous system involvement by Waldenström macroglobulinaemia (Bing‐Neel syndrome): a multi‐institutional retrospective study

A. Norden, E. Lee, S. Treon, 2016, British journal of haematology.

Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database

S. Treon, Z. Hunter, J. Castillo, 2015, British journal of haematology.

Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia.

S. Treon, J. W. Mcmeel, M. Menke, 2008, Investigative ophthalmology & visual science.

Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.

Robert M Hoffman, N. Munshi, N. Mitsiades, 2003, Cancer research.

Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia.

T. Reiman, L. Pilarski, M. Mant, 2005, Clinical lymphoma.

Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib

S. Treon, J. Castillo, S. Sarosiek, 2023, British journal of haematology.

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia

C. Buske, S. Treon, J. Castillo, 2022, American journal of hematology.

Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations

S. Treon, P. Gokhale, Z. Hunter, 2021, Blood.

Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone.

M. Urashima, A. Ogata, L. Pilarski, 1999, Blood.

Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia

S. Treon, K. Meid, J. Castillo, 2016, American journal of hematology.

miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth

N. Munshi, M. Samur, A. Neri, 2016, Blood Cancer Journal.

Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191

R. Davis, V. Baladandayuthapani, S. Ansell, 2018, Clinical Cancer Research.

Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells That Is Accompanied By ERK1/2 Hyperactivation, and Is Targeted By the Addition of the ERK1/2 Inhibitor Ulixertinib

S. Treon, Z. Hunter, J. Castillo, 2016 .

Management of Waldenström macroglobulinemia in 2020.

S. Treon, J. Castillo, 2020, Hematology. American Society of Hematology. Education Program.

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia

R. Advani, J. Laubach, S. Treon, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MONOCLONAL GAMMOPATHIES OF DETERMINED SIGNIFICANCE Management of Waldenström macroglobulinemia in 2020

S. Treon, J. Castillo, 2020 .

What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy.

S. Treon, J. Castillo, 2017, Blood advances.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

M. Dimopoulos, C. Buske, S. Treon, 2017, The Lancet. Oncology.

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.

R. Advani, E. Kimby, M. Dimopoulos, 2016, Blood.

Microrna Expression Profile Identifies Distinct Clinically Relevant Sub-Groups in Multiple Myeloma: Novel Prognostic Markers and Potential Targets for Therapy

N. Munshi, Cheng Li, S. Treon, 2008 .

Diagnosis and management of Waldenstrom's macroglobulinemia.

Robert A Kyle, M. Dimopoulos, R. Kyle, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Initial Evaluation of the Patient with Waldenström Macroglobulinemia.

S. Treon, J. Castillo, 2018, Hematology/oncology clinics of North America.

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status

N. Munshi, A. Ballestrero, M. Gobbi, 2016, Clinical Cancer Research.

Survival outcomes of secondary cancers in patients with waldenström macroglobulinemia: An analysis of the SEER database

S. Treon, Z. Hunter, J. Castillo, 2015, American journal of hematology.

Extramedullary Waldenström macroglobulinemia

J. Laubach, E. Morgan, S. Treon, 2015, American journal of hematology.

Waldenström macroglobulinemia: from biology to treatment

S. Treon, I. Ghobrial, I. Sahin, 2014, Expert review of hematology.

Proteasome inhibitors in Waldenström macroglobulinemia.

S. Treon, 2013, Blood.

Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RAD001) As Primary Therapy In Waldenstrom’s Macroglobulinemia

R. Advani, S. Treon, I. Ghobrial, 2011 .

Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.

S. Treon, L. Ioakimidis, R. Manning, 2011, Clinical lymphoma, myeloma & leukemia.

Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom's macroglobulinemia (WM).

S. Treon, Z. Hunter, L. Ioakimidis, 2010 .

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

P. Richardson, A. Dispenzieri, D. DeAngelo, 2009 .

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.

S. Treon, Z. Hunter, A. Branagan, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

R. Advani, E. Kimby, B. Barlogie, 2014, Blood.

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.

J. Byrd, E. Kimby, D. Agus, 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

N. Munshi, P. Richardson, N. Mitsiades, 2002, Blood.

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma

P. Richardson, D. Kufe, D. Chauhan, 2004, British journal of haematology.

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2016, Blood.

Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia

S. Treon, A. Roccaro, I. Ghobrial, 2008, Leukemia & lymphoma.

Multiple myeloma, version 1.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience

R. Advani, S. Treon, J. Castillo, 2016, Therapeutic advances in hematology.

International Prognostic Scoring System (IPSS) for Waldenström’s Macroglobulinemia (WM).

B. Barlogie, M. Dimopoulos, M. Dhodapkar, 2006 .

Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia

S. Treon, Z. Hunter, J. Castillo, 2018, British journal of haematology.

Rituximab intolerance in patients with Waldenström macroglobulinaemia

S. Treon, Z. Hunter, J. Castillo, 2016, British journal of haematology.

MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.

N. Munshi, P. Tassone, S. Treon, 2014, Blood.

in Waldenström macroglobulinemia MYD88-independent growth and survival effects of Sp1 transactivation

P. Tassone, S. Treon, Z. Hunter, 2014 .

Waldenstrom ' s macroglobulinemia MYD 88-independent growth and survival effects of Sp 1 transactivation in

N. Munshi, P. Tassone, S. Treon, 2014 .

LYMPHOID NEOPLASIA MYD 88-independent growth and survival effects of Sp 1 transactivation in Waldenström macroglobulinemia

N. Munshi, P. Tassone, S. Treon, 2014 .

Fcγ receptor predictive genomic testing and the treatment of indolent non-Hodgkin lymphoma.

S. Treon, 2010, Clinical lymphoma, myeloma & leukemia.

The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.

N. Munshi, N. Gray, Jinhua Wang, 2021, Blood.

Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma

D. McMillin, Jake E. Delmore, P. Richardson, 2012, Molecular Cancer Therapeutics.

Epigenomics in Waldenstrom's macroglobulinaemia.

S. Treon, A. Roccaro, A. Sacco, 2016, Best practice & research. Clinical haematology.

Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events.

A. LaCasce, M. Davids, N. LeBoeuf, 2019, Journal of the American Academy of Dermatology.

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2017, Expert review of hematology.

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.

N. Gray, Jinhua Wang, S. Treon, 2018, Blood.

BTK drives ibrutinib resistance via ERK1/2, and protects BTK MYD88 mutated cells by a paracrine mechanism

Amanda, N. Gray, Jinhua Wang, 2018 .

Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity

S. Treon, Z. Hunter, J. Castillo, 2017, Leukemia & lymphoma.

Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström's Macroglobulinemia

F. Dammacco, S. Treon, A. Roccaro, 2008, Clinical Cancer Research.

Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia.

Hsiuyi Tseng, S. Rodig, S. Treon, 2011, Clinical lymphoma, myeloma & leukemia.

The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions

S. Treon, A. Roccaro, A. Sacco, 2017, Oncotarget.

Venetoclax in Previously Treated Waldenström Macroglobulinemia

R. Advani, M. Davids, S. Treon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The BCL2 antagonist ABT‐199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild‐type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cells

M. Davids, S. Treon, Z. Hunter, 2015, British journal of haematology.

Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy

S. Treon, Z. Hunter, A. Branagan, 2021, Blood advances.

Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia

S. Treon, Z. Hunter, A. Branagan, 2021, British journal of haematology.

Partial response or better at six months is prognostic of superior progression‐free survival in Waldenström macroglobulinaemia patients treated with ibrutinib

R. Advani, S. Treon, S. Ansell, 2020, British journal of haematology.

The race to stymie BTK: zanu zings

S. Treon, P. Kapoor, 2020, Blood.

Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2020, Blood advances.

Genomic evolution of ibrutinib‐resistant clones in Waldenström macroglobulinaemia

S. Treon, Z. Hunter, J. Castillo, 2020, British journal of haematology.

A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2020, Leukemia & lymphoma.

Comparative genomics of CXCR4 MUT and CXCR4 WT single cells in Waldenstr¨om ’ s macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2020 .

Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2019, American journal of hematology.

Genomic landscape of Waldenström's macroglobulinemia

S. Treon, Z. Hunter, A. Branagan, 2019, HemaSphere.

MYD88 mutated and wild-type Waldenström’s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4

M. Cazzola, S. Treon, Z. Hunter, 2018, Haematologica.

MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia

S. Treon, Z. Hunter, J. Castillo, 2018, British journal of haematology.

Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia

S. Treon, I. Ghobrial, Z. Hunter, 2017, British journal of haematology.

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)

S. Treon, I. Ghobrial, Z. Hunter, 2016, Clinical Cancer Research.

Detection Of MYD88 L265P In Peripheral Blood Of Patients With Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy Of Undetermined Significance

N. Lindeman, S. Treon, Z. Hunter, 2013 .

Phase I study of Ibrutinib and the CXCR4 antagonist Ulocuplumab in CXCR4 mutated Waldenstrom Macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2021, Blood.

Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.

G. Pinkus, N. Munshi, S. Treon, 2019, Blood advances.

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

N. Gray, S. Treon, Y. Tai, 2013, Blood.

Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database

S. Treon, Z. Hunter, J. Castillo, 2015, Cancer.

Biology, prognosis, and therapy of Waldenström Macroglobulinemia.

S. Treon, I. Ghobrial, J. Castillo, 2015, Cancer treatment and research.

Genetic Linkage of FcgγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy

M. Hansen, S. Verselis, E. Fox, 2007 .

Investigation and management of IgM and Waldenström‐associated peripheral neuropathies: recommendations from the IWWM‐8 consensus panel

M. Kersten, M. Dimopoulos, S. Treon, 2017, British journal of haematology.

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.

N. Mitsiades, S. Treon, R. Schlossman, 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia

D. Dorfman, S. Treon, T. Hideshima, 2022, International journal of cancer.

Immunotherapeutic strategies for the treatment of plasma cell malignancies.

S. Treon, N. Raje, K. Anderson, 2000, Seminars in oncology.

Attainment of complete/very good partial response following rituximab‐based therapy is an important determinant to progression‐free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

Hsiuyi Tseng, S. Verselis, E. Fox, 2011, British journal of haematology.

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

S. Treon, N. Raje, Z. Hunter, 2017 .

Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia

M. Dimopoulos, R. Kyle, S. Treon, 2016, British journal of haematology.

Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia.

S. Treon, J. W. Mcmeel, M. Menke, 2009, Clinical lymphoma & myeloma.

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.

R. Advani, M. Kersten, M. Dimopoulos, 2020, The Lancet. Haematology.

Clinical Characteristics and Treatment Outcome Of CNS Involvement (Bing-Neel Syndrome) In Waldenstrom’s Macroglobulinemia

A. Norden, E. Lee, S. Treon, 2013 .

Clinical Characteristics of Rituximab Intolerance in Patients with Waldenstrom's Macroglobulinemia

S. Treon, J. Castillo, K. Meid, 2014 .

International prognostic scoring system for Waldenström s Macroglobulinemia Short title: Prognostic index for Waldenström Macroglobulinemia

J. Crowley, B. Barlogie, M. Dimopoulos, 2017 .

How I treat Waldenstr¨ om macroglobulinemia

S. Treon, 2015 .

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

S. Treon, I. Ghobrial, Z. Hunter, 2013 .

Thalidomide and rituximab in Waldenstrom macroglobulinemia.

M. Pasmantier, S. Treon, Z. Hunter, 2004, Blood.

Chapter 87 – Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma

S. Treon, Z. Hunter, G. Merlini, 2008 .

CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.

S. Treon, Z. Hunter, Andrew R Barnagan, 2005, Clinical lymphoma.

Combination Therapy with Rituximab and Fludarabine in Waldenstrom’s Macroglobulinemia.

E. Kimby, P. Morel, S. Treon, 2004 .

Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2018, American journal of hematology.

CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia.

D. Dorfman, S. Treon, Z. Hunter, 2005, Clinical lymphoma.

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.

L. Trippa, M. Dimopoulos, R. Kyle, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment Recommendations in Waldenström Macroglobulinemia

M. Dimopoulos, S. Treon, V. Leblond, 2017 .

Characterization of familial Waldenstrom's macroglobulinemia.

C. Lee, C. Morton, S. Treon, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.

N. Munshi, S. Treon, M. Fulciniti, 2011, Clinical lymphoma, myeloma & leukemia.

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

P. Richardson, S. Treon, I. Ghobrial, 2010 .

Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy.

J. Tamburini, P. Morel, S. Treon, 2009, Clinical lymphoma & myeloma.

A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib

S. Treon, J. Castillo, S. Sarosiek, 2022, EJHaem.

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

M. Dimopoulos, C. Buske, S. Treon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial

M. Dimopoulos, C. Buske, S. Treon, 2021, Clinical Cancer Research.

Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial

R. Advani, J. Laubach, S. Treon, 2017 .

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.

Wei Zhang, P. Cohen, Shuai Liu, 2016, Blood.

CXCR4 WHIM‐like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88L265P‐directed survival signalling in Waldenström macroglobulinaemia cells

S. Treon, Z. Hunter, J. Castillo, 2015, British journal of haematology.

macroglobulinemia Long term outcomes to fludarabine and rituximab in Waldenstrom

P. Morel, S. Treon, A. Branagan, 2008 .

Long-term responses to thalidomide and rituximab in Waldenstrom's macroglobulinemia

S. Treon, Z. Hunter, A. Branagan, 2007 .

Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's macroglobulinemia (WM) patients treated with nucleoside analogues

S. Treon, A. Roccaro, I. Ghobrial, 2007 .

Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.

S. Treon, I. Ghobrial, Z. Hunter, 2006 .

Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: Results of WMCTG trial 02-079.

S. Treon, Z. Hunter, B. Kahl, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Report of the Third International Workshop on Waldenstrom's macroglobulinemia.

P. Morel, S. Treon, V. Leblond, 2005, Clinical lymphoma.

Clinical responses to sildenafil in Waldenstrom's macroglobulinemia.

S. Treon, Z. Hunter, E. Hatjiharissi, 2004, Clinical lymphoma.

CD52 Is Expressed on Human Mast Cells and Is a Therapeutic Target for the Anti-CD52 Monoclonal Antibody Campath-1H in Waldenstrom’s Macroglobulinemia and Mast Cell Disorders.

S. Treon, Z. Hunter, A. Branagan, 2004 .

A prognostic index predicting survival in transformed Waldenström macroglobulinemia

M. Dimopoulos, S. Leprêtre, P. Morel, 2020, Haematologica.

The real world of Waldenström's macroglobulinaemia.

S. Treon, J. Castillo, 2018, The Lancet. Haematology.

Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia

S. Treon, Z. Hunter, A. Branagan, 2021, HemaSphere.

Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia

R. Advani, M. Davids, S. Treon, 2018, Clinical Lymphoma Myeloma and Leukemia.

Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study

M. Dimopoulos, C. Buske, S. Treon, 2018, Blood.

To select or not to select? The role of B‐cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia

S. Treon, Z. Hunter, J. Castillo, 2017, British journal of haematology.

Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database.

S. Treon, Z. Hunter, J. Castillo, 2014, Blood.

Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.

Y. Shima, L. Pilarski, A. Belch, 1999, Seminars in oncology.

Workshop on Waldenström's Macroglobulinemia Update on treatment recommendations from the Third International

E. Kimby, M. Dimopoulos, D. Maloney, 2008 .

CHOP Plus Rituximab (CHOP-R) in Waldenström’s Macroglobulinemia (WM).

S. Treon, Z. Hunter, A. Branagan, 2004 .

Campath-1H in Waldenström’s Macroglobulinemia.

S. Treon, Z. Hunter, A. Branagan, 2004 .

Lymphoplasmacytic Cells and Mast Cells Are Targets for Imatinib Mesylate (Gleevec, Glivec) in Waldenstrom’s Macroglobulinemia.

S. Treon, Z. Hunter, E. Hatjiharissi, 2004 .

Somatic Activating Mutations In CXCR4 Are Common In Patients With Waldenstrom’s Macroglobulinemia, and Their Expression In WM Cells Promotes Resistance To Ibrutinib

S. Treon, Z. Hunter, Guang Yang, 2013 .

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

R. Advani, J. Laubach, S. Treon, 2013 .

Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

S. Treon, Z. Hunter, A. Branagan, 2022, Blood.

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

P. Richardson, S. Treon, I. Ghobrial, 2009 .

Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenström Macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2016 .

Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2018, American journal of hematology.

Lower Doses of Bendamustine Are Not Associated with Lower Response Rates in Previously Untreated Patients with Waldenström Macroglobulinemia

S. Treon, I. Ghobrial, J. Castillo, 2016 .

The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability

R. Advani, N. Munshi, J. Zehnder, 2015 .

Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling.

J. Kutok, S. Treon, Y. Tai, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunomodulatory Agents and Proteasome Inhibitors in Waldenstrom’s Macroglobulinemia

M. Dimopoulos, S. Treon, E. Kastritis, 2017 .

Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.

Hsiuyi Tseng, S. Treon, E. Hatjiharissi, 2009, Clinical lymphoma & myeloma.

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

P. Richardson, S. Treon, I. Ghobrial, 2009 .

Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study.

S. Treon, I. Ghobrial, V. Leblond, 2009 .

Phase II Study of Bortezomib in Waldenstrom’s Macroglobulinemia: Results of WMCTG Trial 03-248.

R. Advani, S. Treon, Z. Hunter, 2005 .

Application and Outcomes of Bendamustine- or Bortezomib-Based Therapy for Waldenstrom's Macroglobulinemia

S. Treon, J. Castillo, A. Olszewski, 2017 .

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study

M. Dimopoulos, C. Buske, S. Treon, 2020 .

Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia

S. Treon, I. Ghobrial, J. Castillo, 2015 .

Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2018, Blood.

Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM)

D. Siegel, S. Treon, N. Raje, 2014 .

Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27.

Hsiuyi Tseng, S. Treon, Jingrui Jiang, 2011, Clinical lymphoma, myeloma & leukemia.

Comparative Outcomes Following CP-R, CVP-R and CHOP-R in Patients with Waldenstrom’s Macroglobulinemia.

S. Treon, L. Ioakimidis, C. Patterson, 2008 .

Comprehensive Assessment of Cytokines and Chemokines In Patients with Waldenstrom's Macroglobulinemia Reveals a Distinct Profile with Pathobiological and Clinical Relevance

S. Treon, Z. Hunter, B. Ciccarelli, 2010 .

Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia

N. Gray, S. Treon, Z. Hunter, 2017, British journal of haematology.

Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia

P. Cohen, N. Gray, S. Treon, 2015 .

Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia

S. Treon, I. Ghobrial, Z. Hunter, 2007, American journal of hematology.

IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.

G. Parmigiani, N. Munshi, M. Mohty, 2021, Blood.

Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age

S. Treon, Z. Hunter, J. Castillo, 2018, British journal of haematology.

Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.

S. Ansell, E. Morgan, S. Treon, 2020, Blood advances.

Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia

S. Treon, Z. Hunter, J. Castillo, 2019, British journal of haematology.

Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib

S. Treon, J. Castillo, M. Cheng, 2018, British journal of haematology.

Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia

R. Advani, S. Treon, Z. Hunter, 2018, Haematologica.

Comparative response assessment by total serum IgM and IgM M-component in Waldenstrom’s macroglobulinemia.

S. Treon, Z. Hunter, L. Ioakimidis, 2012 .

Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia

Michael L. Wang, R. Orlowski, S. Treon, 2012 .

Waldenström macroglobulinemia lymphoplasmacytic cells by activation of Bruton tyrosine kinase in A mutation in MYD88 (L265P) supports the survival of

N. Gray, S. Treon, Z. Hunter, 2014 .

Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias

N. Mitsiades, C. Mitsiades, S. Treon, 2001, Expert opinion on investigational drugs.

Reply to F.D. Leonard.

S. Treon, I. Ghobrial, J. Castillo, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Signal Inhibitors in Waldenstrom’s Macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2017 .

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATETM)

M. Dimopoulos, C. Buske, S. Treon, 2015 .

Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood.

L. Pilarski, M. Mant, A. Belch, 2004, Blood.

Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATETM Trial

M. Dimopoulos, C. Buske, S. Treon, 2020 .

Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia

S. Treon, I. Ghobrial, J. Castillo, 2015, American journal of hematology.

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas

N. Gray, Jinhua Wang, S. Treon, 2020, Blood Cancer Journal.

Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation

S. Treon, I. Ghobrial, J. Castillo, 2016, Leukemia & lymphoma.

Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia.

S. Treon, T. Hideshima, H. Ngo, 2006 .

CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.

J. Kutok, S. Treon, Y. Tai, 2006, Clinical lymphoma & myeloma.

Epigenomics in Waldenström macroglobulinemia.

S. Treon, Z. Hunter, 2020, Blood.

Thalidomide in Combination with Rituximab Is Active in Waldenström’s Macroglobulinemia and May Overcome Poor Response Determinants Associated with Rituximab Monotherapy.

S. Treon, Z. Hunter, A. Branagan, 2005 .

Phase II Study of CC-5013 (Revlimid) and Rituximab in Waldenström’s Macroglobulinemia: Preliminary Safety and Efficacy Results.

S. Treon, Z. Hunter, A. Branagan, 2005 .

MYD88 L265P Promotes Survival of Waldenstrom's Macroglobulinemia Cells by Activation of Bruton's Tyrosine Kinase

S. Treon, Y. Tai, Z. Hunter, 2012 .

Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia

L. Trippa, M. Dimopoulos, R. Kyle, 2019, Clinical Lymphoma Myeloma and Leukemia.

Incidence and Survival Outcomes of Secondary Malignancies Among Survivors of Waldenström Macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2014, Blood.

Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis.

S. Treon, G. Merlini, J. San-Miguel, 2023, Seminars in hematology.

of polyclonal B cells in peripheral blood macroglobulinemia suggests an unusual B-cell origin and an expansion Clonotypic IgM V/D/J sequence analysis in Waldenstrom

M. Mant, A. Belch, S. Treon, 2008 .

The malignant clone in Waldenstrom's macroglobulinemia.

L. Pilarski, M. Mant, A. Belch, 2003, Seminars in oncology.

and therapeutic implications (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity Specific killing of multiple myeloma cells by

N. Munshi, R. Batchu, R. Goyal, 2008 .

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

E. Kimby, P. Morel, S. Treon, 2023, Seminars in Hematology.

The High Risk for Symptomatic Hyperviscosity in Patients with High Serum IgM Levels Can be Used to Support Initiation of Treatment in Waldenström Macroglobulinemia

S. Treon, I. Ghobrial, J. Castillo, 2016 .

Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma

Y. Shima, D. Chauhan, S. Treon, 2000 .

Profiling of Circulating Exosomes in Patients with Waldenström Macroglobulinemia

M. Capelletti, S. Treon, A. Roccaro, 2016 .

Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome.

A. Patriarca, S. Treon, E. Kastritis, 2021, Blood.

High Levels of Soluble Immunoregulatory Receptors in Patients with WaldenströM’s Macroglobulinemia.

S. Treon, Z. Hunter, E. Hatjiharissi, 2004 .

Clinical Responses to Sildenafil in Waldenstrom’s Macroglobulinemia.

S. Treon, Z. Hunter, E. Hatjiharissi, 2004 .

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

E. Kimby, P. Morel, S. Treon, 2023, Seminars in Hematology.

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

M. Dimopoulos, C. Buske, V. Garg, 2021, Blood.

The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells

G. Pinkus, Jian-jun Zhao, Catherine J. Wu, 2015, Nature Medicine.

Activity of the NEDD8-specific inhibitor MLN 4924 in multiple myeloma and Waldenström's macroglobulinemia, and effect on miRNA expression.

K. Anderson, D. McMillin, Jake E. Delmore, 2010 .

Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE.

M. Dimopoulos, C. Buske, D. Macdonald, 2019, Journal of Clinical Oncology.

The Cyclophilin A-CD147 complex promotes bone marrow colonization of B-cell malignancies: implications for therapy

G. Pinkus, Jian-jun Zhao, Catherine J. Wu, 2015, Nature medicine.

A Humanized Anti-CD70 Monoclonal Antibody Targets CD70-Expressing Multiple Myeloma.

N. Munshi, P. Carter, A. Wahl, 2005 .

Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.

M. Hansen, S. Verselis, E. Fox, 2007, Clinical lymphoma & myeloma.

Comparing Apples to Oranges : A commentary on the Mayo study of MYD 88 significance in Waldenstrom ’

S. Treon, Z. Hunter, J. Castillo, 2017 .

Comment on Poulain Et Al, Page 4504

S. Treon, Z. Hunter, 2022 .

Use of whole genome sequencing to identify highly recurrent somatic mutations in Waldenström’s macroglobulinemia.

S. Treon, Z. Hunter, Guang Yang, 2012 .

Disruption of MYD88 Pathway Signaling Leads to Loss of Constitutive IRAK1, NF-κβ and JAK/STAT Signaling and Induces Apoptosis of Cells Expressing the MYD88 L265P Mutation in Waldenstrom's Macroglobulinemia

S. Treon, Z. Hunter, Guang Yang, 2011 .

Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration.

S. Treon, Z. Hunter, B. Ciccarelli, 2013, Clinical lymphoma, myeloma & leukemia.

Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom’s Macroglobulinemia.

F. Dammacco, S. Treon, A. Roccaro, 2007 .

Abnormalities in Lipoprotein Metabolism Provide Insight into Novel Therapeutic Approaches for Waldenstrom’s Macroglobulinemia (WM).

S. Treon, Z. Hunter, X. Leleu, 2006 .

Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenström’s Macroglobulinemia (WM).

N. Munshi, S. Treon, Z. Hunter, 2006 .

Therapeutic targeting of CD70 and CD27-CD70 interactions with the monoclonal antibody SGN-70 in Waldenstrom's Macroglobulinemia (WM).

S. Treon, Z. Hunter, E. Hatjiharissi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia.

S. Treon, I. Ghobrial, Z. Hunter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

B-Lymphocyte Stimulator Protein (BLYS) Is Expressed by Bone Marrow Mast and Lymphoplasmacytic Cells in Waldenstrom’s Macroglobulinemia, and Provides Signaling for Growth, Survival and IgM Secretion.

S. Treon, Z. Hunter, A. Branagan, 2004 .

Microarray Analysis of the Peripheral Monocytes From Waldenstrom's Macroglobulinemia Patients Reveals a Distinct Gene Expression Profile

S. Treon, Jingrui Jiang, Z. Hunter, 2010 .

IgA and IgG Hypogammaglobulinemia Are Associated with Mutations in the APRIL/BLYS Receptor TACI in Waldenstrom’s Macroglobulinemia (WM).

S. Verselis, E. Fox, S. Treon, 2006 .

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

P. Richardson, Lei Wu, Y. Shima, 2001, Leukemia.

Hepatitis C Viral Infection Is Not Associated with Waldenstrom’s Macroglobulinemia.

S. Treon, Z. Hunter, X. Leleu, 2005 .

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

G. Morgan, P. Richardson, D. Chauhan, 2001, Blood.

Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling

Robert M. Vogel, C. Ziegler, G. Altan-Bonnet, 2016, Leukemia.

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia

P. Richardson, P. Armand, S. Treon, 2015, Leukemia.

The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia

S. Rodig, S. Treon, J. Chen, 2014, Leukemia.

Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

N. Lindeman, S. Treon, J. Chen, 2014, Leukemia.

Plenary Paper

S. Treon, Z. Hunter, Guang Yang, 2014 .

Participation of BTK in MYD88 signaling in malignant cells expressing the L265P mutation in Waldenstrom’s macroglobulinemia, and effect on tumor cells with BTK-inhibitor PCI-32765 in combination with MYD88 pathway inhibitors.

S. Treon, Y. Tai, Z. Hunter, 2012 .

IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

M. Urashima, A. Ogata, G. Teoh, 1997, Journal of immunology.

Waldenström's macroglobulinemia.

M. Dimopoulos, S. Treon, G. Merlini, 1994, Hematology/oncology clinics of North America.

Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care.

S. Treon, C. Patterson, R. G. Sanz, 2023, Seminars in hematology.

P1159: A MULTICENTER, INTERNATIONAL COLLABORATIVE STUDY EVALUATING FRONTLINE THERAPY WITH BENDAMUSTINE RITUXIMAB FOR WALDENSTRÖM MACROGLOBULINEMIA

S. Treon, A. Delmer, E. Durot, 2022, HemaSphere.

Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.

M. Dimopoulos, R. Kyle, Shaji K. Kumar, 2022, Journal of Clinical Oncology.

CD 40 induces human multiple myeloma cell migration via phosphatidylinositol 3 – kinase / AKT / NF-B signaling

N. Munshi, N. Mitsiades, C. Mitsiades, 2003 .

Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia

L. Trippa, D. Steensma, S. Treon, 2021, Blood advances.

Diagnosis and management of Waldenstrom's macroglobulinemia.

M. Dimopoulos, R. Kyle, S. Treon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-estrogens induce apoptosis of multiple myeloma cells.

M. Urashima, A. Ogata, G. Teoh, 1998, Blood.

HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma

N. Gray, S. Treon, Z. Hunter, 2015 .

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

P. Richardson, N. Mitsiades, C. Mitsiades, 2001, Blood.

Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.

J. Gribben, S. Treon, F. Marty, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Isolation and characterization of human multiple myeloma cell enriched populations.

Y. Shima, G. Teoh, D. Chauhan, 2000, Journal of immunological methods.

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2012, The Journal of the National Comprehensive Cancer Network.

Comprehensive Molecular Characterization of Malignant and Microenvironmental Cells in Waldenstrom’s Macroglobulinemia by Gene Expression Profiling.

C. Mitsiades, S. Treon, A. Roccaro, 2007 .

Preclinical Development Molecular and Cellular Effects of NEDD 8-Activating Enzyme Inhibition in Myeloma

D. McMillin, Jake E. Delmore, P. Richardson, 2012 .

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells

Ryan D. Morin, R. Gascoyne, J. Connors, 2015, Clinical Cancer Research.

Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias.

N. Mitsiades, C. Mitsiades, S. Treon, 2003, Seminars in oncology.

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.

J. Kutok, N. Munshi, P. Richardson, 2010, Blood.

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2006, Blood.

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

G. Morgan, P. Richardson, D. Chauhan, 2001, Blood.

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

E. Kimby, P. Morel, S. Treon, 2023, Seminars in Hematology.

Conflicts of interest, authorship, and disclosures in industry-related scientific publications.

B. Barlogie, J. Shaughnessy, R. Fonseca, 2010, Mayo Clinic proceedings.

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.

P. Richardson, S. Ansell, A. Dispenzieri, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

N. Munshi, N. Lindeman, S. Treon, 2013, Blood.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

R. Advani, N. Harris, J. Aster, 2015, The New England journal of medicine.

Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia

S. Treon, I. Ghobrial, J. Castillo, 2015, American journal of hematology.

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia

Michael L. Wang, V. Baladandayuthapani, S. Ansell, 2015, Clinical Cancer Research.

Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.

E. Kimby, M. Dimopoulos, R. Kyle, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

S. Treon, Z. Hunter, J. Castillo, 2019, British journal of haematology.

Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia

N. Gray, S. Treon, Z. Hunter, 2017, British journal of haematology.

To select or not to select? The role of B‐cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia

S. Treon, Z. Hunter, J. Castillo, 2017, British journal of haematology.

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2016, Blood.

Absence of somatic MYD88 L265P mutations in patients with primary Sjogren’s syndrome

S. Treon, H. Moutsopoulos, M. Voulgarelis, 2013, Genes and Immunity.

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

P. Richardson, Y. Shima, D. Chauhan, 2000 .

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

M. Dimopoulos, C. Buske, P. Marlton, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences.

Dongshu Chen, G. Teoh, D. Chauhan, 1999, Blood.

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias

P. Richardson, S. Treon, A. Roccaro, 2008, Biologics : targets & therapy.

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.

E. Kimby, P. Morel, S. Treon, 2008, Blood.

Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia

M. Dimopoulos, R. Kyle, S. Treon, 2016, British journal of haematology.

How I treat Waldenström macroglobulinemia.

S. Treon, 2009, Blood.

The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells.

K. Anderson, M. Urashima, A. Ogata, 1998, The Journal of clinical investigation.

Detection of Kaposi's Sarcoma Herpesvirus Gene Sequences Multiple Myeloma Are Phenotypically and Functionally Normal Despite the Bone Marrow and Peripheral Blood Dendritic Cells From Patients With

D. Kufe, G. Teoh, D. Chauhan, 2008 .

BTKCys481Ser Mutation Drives Ibrutinib Resistance through ERK1/2 Hyperactivation, and Can Confer a Protective Effect on Bystander Waldenstrom's Macroglobulinemia and ABC DLBCL Cells through Paracrine Mediated Pro-Survival Signaling

S. Treon, Z. Hunter, J. Castillo, 2017 .

Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia

R. Advani, S. Treon, Z. Hunter, 2016 .

High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia

M. Dimopoulos, S. Leprêtre, P. Morel, 2022, Blood advances.

Thalidomide and rituximab in Waldenstrom macroglobulinemia.

M. Pasmantier, S. Treon, Z. Hunter, 2004, Blood.